List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9499012/publications.pdf Version: 2024-02-01



DED KADSSON

#	Article	IF	CITATIONS
1	Surgical outcome of graded Harada-Ito procedure in the treatment of torsional diplopia ‒ a retrospective case study with long-term results. Strabismus, 2022, 30, 8-17.	0.4	1
2	Breast cancer hypoxia in relation to prognosis and benefit from radiotherapy after breast-conserving surgery in a large, randomised trial with long-term follow-up. British Journal of Cancer, 2022, 126, 1145-1156.	2.9	20
3	Tumour-infiltrating lymphocytes add prognostic information for patients with low-risk DCIS: findings from the SweDCIS randomised radiotherapy trial. European Journal of Cancer, 2022, 168, 128-137.	1.3	6
4	Immune Infiltrate in the Primary Tumor Predicts Effect of Adjuvant Radiotherapy in Breast Cancer; Results from the Randomized SweBCG91RT Trial. Clinical Cancer Research, 2021, 27, 749-758.	3.2	10
5	Genomic Aberrations and Late Recurrence in Postmenopausal Women with Hormone Receptor–positive Early Breast Cancer: Results from the SOLE Trial. Clinical Cancer Research, 2021, 27, 504-512.	3.2	5
6	Prognostic and predictive impact of stroma cells defined by PDGFRb expression in early breast cancer: results from the randomized SweBCG91RT trial. Breast Cancer Research and Treatment, 2021, 187, 45-55.	1.1	8
7	Prognostic Significance of BIRC5/Survivin in Breast Cancer: Results from Three Independent Cohorts. Cancers, 2021, 13, 2209.	1.7	29
8	High PDGFRb Expression Predicts Resistance to Radiotherapy in DCIS within the SweDCIS Randomized Trial. Clinical Cancer Research, 2021, 27, 3469-3477.	3.2	8
9	Genetic alterations associated with multiple primary malignancies. Cancer Medicine, 2021, 10, 4465-4477.	1.3	7
10	Discovery and validation of a genomic signature to identify women with early-stage invasive breast cancer who may safely omit adjuvant radiotherapy after breast-conserving surgery Journal of Clinical Oncology, 2021, 39, 512-512.	0.8	3
11	Prognostic Risk Assessment and Prediction of Radiotherapy Benefit for Women with Ductal Carcinoma In Situ (DCIS) of the Breast, in a Randomized Clinical Trial (SweDCIS). Cancers, 2021, 13, 6103.	1.7	21
12	Locally advanced breast cancer. Breast, 2021, , .	0.9	9
13	A 17-marker panel for global genomic instability in breast cancer. Genomics, 2020, 112, 1151-1161.	1.3	18
14	Previously diagnosed multiple primary malignancies in patients with breast carcinoma in Western Sweden between 2007 and 2018. Breast Cancer Research and Treatment, 2020, 184, 221-228.	1.1	9
15	Expression of HGF, pMet, and pAkt is related to benefit of radiotherapy after breastâ€conserving surgery: a longâ€ŧerm followâ€up of the SweBCG91â€RT randomised trial. Molecular Oncology, 2020, 14, 2713-2726.	2.1	2
16	Integrative genomics approach identifies molecular features associated with early-stage ovarian carcinoma histotypes. Scientific Reports, 2020, 10, 7946.	1.6	14
17	Comprehensive Transcriptomic Profiling Identifies Breast Cancer Patients Who May Be Spared Adjuvant Systemic Therapy. Clinical Cancer Research, 2020, 26, 171-182.	3.2	14
18	Validation of Novel Prognostic Biomarkers for Early-Stage Clear-Cell, Endometrioid and Mucinous Ovarian Carcinomas Using Immunohistochemistry. Frontiers in Oncology, 2020, 10, 162.	1.3	27

#	Article	IF	CITATIONS
19	Optimization of cell viability assays to improve replicability and reproducibility of cancer drug sensitivity screens. Scientific Reports, 2020, 10, 5798.	1.6	106
20	No Increased Cardiac Mortality or Morbidity of Radiation Therapy in Breast Cancer Patients After Breast-Conserving Surgery: 20-Year Follow-up of the Randomized SweBCGRT Trial. International Journal of Radiation Oncology Biology Physics, 2020, 107, 701-709.	0.4	19
21	Tumor-infiltrating lymphocytes in ipsilateral breast tumor recurrences predict prognosis Journal of Clinical Oncology, 2020, 38, 546-546.	0.8	0
22	Distribution of Locoregional Breast Cancer Recurrence in Relation to Postoperative Radiation Fields and Biological Subtypes. International Journal of Radiation Oncology Biology Physics, 2019, 105, 285-295.	0.4	15
23	Clinicogenomic Radiotherapy Classifier Predicting the Need for Intensified Locoregional Treatment After Breast-Conserving Surgery for Early-Stage Breast Cancer. Journal of Clinical Oncology, 2019, 37, 3340-3349.	0.8	61
24	Immunohistochemical validation of COL3A1, GPR158 and PITHD1 as prognostic biomarkers in early-stage ovarian carcinomas. BMC Cancer, 2019, 19, 928.	1.1	46
25	Integration of biological factors in the treatment plan evaluation in breast cancer radiotherapy. Physics and Imaging in Radiation Oncology, 2019, 11, 54-60.	1.2	2
26	The prognostic relevance of FOXA1 and Nestin expression in breast cancer metastases: a retrospective study of 164 cases during a 10-year period (2004–2014). BMC Cancer, 2019, 19, 187.	1.1	11
27	Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial. British Journal of Cancer, 2019, 120, 959-967.	2.9	5
28	Radiationâ€induced genomic instability in breast carcinomas of the Swedish hemangioma cohort. Genes Chromosomes and Cancer, 2019, 58, 627-635.	1.5	6
29	Effect of Radiotherapy After Breast-Conserving Surgery Depending on the Presence of Tumor-Infiltrating Lymphocytes: A Long-Term Follow-Up of the SweBCG91RT Randomized Trial. Journal of Clinical Oncology, 2019, 37, 1179-1187.	0.8	41
30	Increased Overall Mortality Even after Risk Reducing Surgery for BRCA-Positive Women in Western Sweden. Genes, 2019, 10, 1046.	1.0	3
31	Positive sentinel node in luminal A-like breast cancer patients - implications for adjuvant chemotherapy?. Acta Oncológica, 2019, 58, 162-167.	0.8	8
32	Breast cancer survival trends in different stages and age groups – a population-based study 1989–2013. Acta Oncológica, 2019, 58, 45-51.	0.8	22
33	Metachronous and Synchronous Occurrence of 5 Primary Malignancies in a Female Patient between 1997 and 2013: A Case Report with Germline and Somatic Genetic Analysis. Case Reports in Oncology, 2018, 10, 1006-1012.	0.3	14
34	Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncology, The, 2018, 19, 127-138.	5.1	91
35	Transcriptomic and genomic profiling of early-stage ovarian carcinomas associated with histotype and overall survival. Oncotarget, 2018, 9, 35162-35180.	0.8	10
36	Clonal relatedness in tumour pairs of breast cancer patients. Breast Cancer Research, 2018, 20, 96.	2.2	14

#	Article	IF	CITATIONS
37	Long-term safety and survival outcomes from the Scandinavian Breast Group 2004-1 randomized phase Il trial of tailored dose-dense adjuvant chemotherapy for early breast cancer. Breast Cancer Research and Treatment, 2018, 168, 349-355.	1.1	5
38	Comprehensive transcriptomic profiling to identify breast cancer patients that may be spared adjuvant systemic therapy Journal of Clinical Oncology, 2018, 36, 535-535.	0.8	1
39	Genome-wide multi-omics profiling of the 8p11-p12 amplicon in breast carcinoma. Oncotarget, 2018, 9, 24140-24154.	0.8	19
40	Mindfulness and its efficacy for psychological and biological responses in women with breast cancer. Cancer Medicine, 2017, 6, 1108-1122.	1.3	95
41	A Novel 18-Marker Panel Predicting Clinical Outcome in Breast Cancer. Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 1619-1628.	1.1	1
42	Postoperative radiotherapy after DCIS: Useful for whom?. Breast, 2017, 34, S43-S46.	0.9	8
43	Response to Radiotherapy After Breast-Conserving Surgery in Different Breast Cancer Subtypes in the Swedish Breast Cancer Group 91 Radiotherapy Randomized Clinical Trial. Journal of Clinical Oncology, 2017, 35, 3222-3229.	0.8	74
44	Long-term safety and survival outcomes from the Scandinavian Breast Group 2004–1 (SBG 2004-1) randomized trial of tailored dose adjuvant chemotherapy for early breast cancer Journal of Clinical Oncology, 2017, 35, e12036-e12036.	0.8	0
45	Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial. Journal of Clinical Oncology, 2016, 34, 1601-1610.	0.8	100
46	Timing of Radiation Therapy and Chemotherapy After Breast-Conserving Surgery for Node-Positive Breast Cancer: Long-Term Results From International Breast Cancer Study Group Trials VI and VII. International Journal of Radiation Oncology Biology Physics, 2016, 96, 273-279.	0.4	22
47	Cyclotorsion Measured in a Patient Population Using Three Different Methods: A Comparative Study. Strabismus, 2016, 24, 28-36.	0.4	10
48	Purposeful Agency in Support Seeking During Cancer Treatment From a Person-Centered Perspective. Global Qualitative Nursing Research, 2016, 3, 233339361663067.	0.7	1
49	Annual Hazard Rates of Recurrence for Breast Cancer During 24 Years of Follow-Up: Results From the International Breast Cancer Study Group Trials I to V. Journal of Clinical Oncology, 2016, 34, 927-935.	0.8	390
50	Radiation Therapy to the Plexus Brachialis inÂBreast Cancer Patients: Analysis of Paresthesia in Relation to Dose and Volume. International Journal of Radiation Oncology Biology Physics, 2015, 92, 277-283.	0.4	16
51	Breast cancer risk and possible mechanisms of radiation-induced genomic instability in the Swedish hemangioma cohort after reanalyzed dosimetry. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2015, 775, 1-9.	0.4	33
52	Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Annals of Oncology, 2015, 26, 1533-1546.	0.6	1,449
53	Effect of Radiotherapy After Breast-Conserving Surgery for Ductal Carcinoma in Situ: 20 Years Follow-Up in the Randomized SweDCIS Trial. Journal of Clinical Oncology, 2014, 32, 3613-3618.	0.8	184
54	Association of Nuclear-Localized Nemo-Like Kinase with Heat-Shock Protein 27 Inhibits Apoptosis in Human Breast Cancer Cells. PLoS ONE, 2014, 9, e96506.	1.1	18

#	Article	IF	CITATIONS
55	Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Annals of Oncology, 2013, 24, 2206-2223.	0.6	2,805
56	Risk Factors of Developing Long-Lasting Breast Pain After Breast Cancer Radiotherapy. International Journal of Radiation Oncology Biology Physics, 2012, 83, 71-78.	0.4	41
57	Timing of Radiotherapy and Outcome in Patients Receiving Adjuvant Endocrine Therapy. International Journal of Radiation Oncology Biology Physics, 2011, 80, 398-402.	0.4	32
58	Symptoms 10–17 years after breast cancer radiotherapy data from the randomised SWEBCG91-RT trial. Radiotherapy and Oncology, 2010, 97, 281-287.	0.3	38
59	Accelerated partial breast cancer irradiation (APBI)–the future breast cancer radiotherapy?. Acta Oncológica, 2009, 48, 485-486.	0.8	1
60	The Role of the Number of Uninvolved Lymph Nodes in Predicting Locoregional Recurrence in Breast Cancer. Journal of Clinical Oncology, 2007, 25, 2019-2026.	0.8	67
61	SPET imaging of central muscarinic acetylcholine receptors with iodine-123 labelled E-IQNP and Z-IQNP. European Journal of Nuclear Medicine and Molecular Imaging, 2001, 28, 13-24.	2.2	12
62	The western Swedish BRCA1 founder mutation 3171ins5; a 3.7 cM conserved haplotype of today is a reminiscence of a 1500-year-old mutation. European Journal of Human Genetics, 2001, 9, 787-793.	1.4	50
63	A Founder Mutation of the BRCA1-Gene in Western Sweden. Disease Markers, 1999, 15, 99-99.	0.6	0
64	Iodine-123 labelled Z -( R , R )-IQNP: a potential radioligand for visualization of M 1 and M 2 muscarinic acetylcholine receptors in Alzheimer's disease. European Journal of Nuclear Medicine and Molecular Imaging, 1999, 26, 1482-1485.	3.3	10
65	Bromine-76 and carbon-11 labelled NNC 13-8199, metabolically stable benzodiazepine receptor agonists as radioligands for positron emission tomography (PET). European Journal of Nuclear Medicine and Molecular Imaging, 1997, 24, 1261-1267.	3.3	14
66	Effects of cocaine on [11C]norepinephrine and [11C]β-CIT uptake in the primate peripheral organs measured by PET. Annals of Nuclear Medicine, 1996, 10, 85-88.	1.2	8
67	[11C]?-CIT-FE, a radioligand for quantitation of the dopamine transporter in the living brain using positron emission tomography. , 1996, 22, 386-390.		76
68	Cancer Incidence after Radiotherapy for Skin Haemangioma During Infancy. Acta Oncológica, 1995, 34, 735-740.	0.8	99
69	Pet study of [11C] β-CIT binding to monoamine transporters in the monkey and human brain. Synapse, 1994, 16, 93-103.	0.6	162